116 related articles for article (PubMed ID: 14747583)
1. Inactivation of transmissible spongiform encephalopathy (prion) agents by environ LpH.
Race RE; Raymond GJ
J Virol; 2004 Feb; 78(4):2164-5. PubMed ID: 14747583
[TBL] [Abstract][Full Text] [Related]
2. New hospital disinfection processes for both conventional and prion infectious agents compatible with thermosensitive medical equipment.
Lehmann S; Pastore M; Rogez-Kreuz C; Richard M; Belondrade M; Rauwel G; Durand F; Yousfi R; Criquelion J; Clayette P; Perret-Liaudet A
J Hosp Infect; 2009 Aug; 72(4):342-50. PubMed ID: 19541387
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of animal and human prions by hydrogen peroxide gas plasma sterilization.
Rogez-Kreuz C; Yousfi R; Soufflet C; Quadrio I; Yan ZX; Huyot V; Aubenque C; Destrez P; Roth K; Roberts C; Favero M; Clayette P
Infect Control Hosp Epidemiol; 2009 Aug; 30(8):769-77. PubMed ID: 19563265
[TBL] [Abstract][Full Text] [Related]
4. Infectivity of prion protein bound to stainless steel wires: a model for testing decontamination procedures for transmissible spongiform encephalopathies.
Yan ZX; Stitz L; Heeg P; Pfaff E; Roth K
Infect Control Hosp Epidemiol; 2004 Apr; 25(4):280-3. PubMed ID: 15108723
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of SE agents.
Taylor DM
Br Med Bull; 1993 Oct; 49(4):810-21. PubMed ID: 8137130
[TBL] [Abstract][Full Text] [Related]
6. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
[TBL] [Abstract][Full Text] [Related]
7. Prion biology relevant to bovine spongiform encephalopathy.
Novakofski J; Brewer MS; Mateus-Pinilla N; Killefer J; McCusker RH
J Anim Sci; 2005 Jun; 83(6):1455-76. PubMed ID: 15890824
[TBL] [Abstract][Full Text] [Related]
8. Prevention of TSE (Transmissible Spongiform Encephalopathies) with synthetic peptides: influence on progression of disease.
Formentin EA; Servida F; Lucchini B; Lauzi S; Ponti W
Vet Res Commun; 2007 Aug; 31 Suppl 1():229-32. PubMed ID: 17682882
[No Abstract] [Full Text] [Related]
9. [Prevention of transmissible spongiform encephalopathy and methods for prion inactivation].
Papacchini M; Mansi A; Marta I
Med Lav; 2003; 94(3):271-84. PubMed ID: 12918319
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of transmissible degenerative encephalopathy agents: A review.
Taylor DM
Vet J; 2000 Jan; 159(1):10-7. PubMed ID: 10640408
[TBL] [Abstract][Full Text] [Related]
11. Transmissible Spongiform Encephalopathy (TSE): vaccinal approach using the hamster model.
Pollera C; Caramelli M; Giannino ML; Martino PA; Puricelli M; Casalone C; Gazzuola P; Poli G
Vet Res Commun; 2004 Aug; 28 Suppl 1():303-6. PubMed ID: 15372983
[No Abstract] [Full Text] [Related]
12. Oral transmissibility of prion disease is enhanced by binding to soil particles.
Johnson CJ; Pedersen JA; Chappell RJ; McKenzie D; Aiken JM
PLoS Pathog; 2007 Jul; 3(7):e93. PubMed ID: 17616973
[TBL] [Abstract][Full Text] [Related]
13. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.
Diez JM; Caballero S; Belda FJ; Otegui M; Gajardo R; Jorquera JI
Haemophilia; 2009 Nov; 15(6):1249-57. PubMed ID: 19563480
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical and biological characterizations of distinct strains of the transmissible mink encephalopathy agent.
Marsh RF; Bessen RA
Philos Trans R Soc Lond B Biol Sci; 1994 Mar; 343(1306):413-4. PubMed ID: 7913759
[TBL] [Abstract][Full Text] [Related]
15. Characterization of thermodynamic diversity between transmissible spongiform encephalopathy agent strains and its theoretical implications.
Somerville RA; Oberthur RC; Havekost U; MacDonald F; Taylor DM; Dickinson AG
J Biol Chem; 2002 Mar; 277(13):11084-9. PubMed ID: 11792707
[TBL] [Abstract][Full Text] [Related]
16. Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.
Diez JM; Caballero S; Belda F; Otegui M; Gajardo R; Jorquera JI
Biologicals; 2010 Nov; 38(6):670-4. PubMed ID: 20863716
[TBL] [Abstract][Full Text] [Related]
17. The prion/lipid hypothesis--further evidence to support the molecular basis for transmissible spongiform encephalopathy risk assessment.
Gale P
J Appl Microbiol; 2007 Dec; 103(6):2033-45. PubMed ID: 18045387
[TBL] [Abstract][Full Text] [Related]
18. [Biology of non-conventional transmissible agents or prions].
Dormont D
Rev Neurol (Paris); 1998 Feb; 154(2):142-51. PubMed ID: 9773035
[TBL] [Abstract][Full Text] [Related]
19. Prions and peripheral nerves: a deadly rendezvous.
Heikenwalder M; Julius C; Aguzzi A
J Neurosci Res; 2007 Sep; 85(12):2714-25. PubMed ID: 17393538
[TBL] [Abstract][Full Text] [Related]
20. Transmissible spongiform encephalopathy agent clearance by the immunoaffinity and anion-exchange chromatography steps of the ReFacto manufacturing process.
Booth J; Vicik S; Tannatt M; Gallo C; Kelley B
Haemophilia; 2007 Sep; 13(5):580-7. PubMed ID: 17880447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
